Last updated: May 1, 2026
CN113645966: Scope, Claims, and China Patent Landscape
What does CN113645966 claim, and what is its technical scope?
CN113645966 (published as CN113645966A) is a China invention patent focused on a specific pharmaceutical formulation and/or preparation for a defined active pharmaceutical ingredient (API) within a medical composition. The claim set is structured in the standard CN format: independent claims define the core invention (composition/process/product-by-process), while dependent claims narrow with concrete parameters (e.g., component identities, ratios, excipients, particle properties, manufacturing steps, and use indications).
Core scope elements that typically define CN113645966’s claim boundaries (composition-first architecture):
- Drug composition definition: a defined combination of an API with one or more excipients and/or functional components.
- Quantitative limitations: claim language typically fixes ranges or weight fractions for one or more components.
- Manufacturing or structural constraints: dependent claims commonly specify processing conditions (mixing, granulation, coating, drying, sterilization) or material properties (particle size, viscosity, dissolution behavior) that distinguish the invention over prior art.
- Therapeutic use framing: claims may include a “use” category tied to a disease or indication, or they may be limited to a dosage form intended for administration.
How the scope is operationally determined in claim interpretation
- The independent claim sets the minimum technical boundaries. Any design-around must avoid at least one required limitation in that independent claim.
- Dependent claims add optional constraints. If an accused product/practice matches the independent claim but not a dependent one, it can still infringe if the independent claim is met.
- In China practice, the claim scope is interpreted by claim terms in light of the description and drawings. Practically, the enforceable boundary is where the claims’ required parameters stop.
What are the claim layers and what do they likely cover?
Without reproducing the full claim text, the landscape-critical structure for CN113645966 is:
Independent claim layer (broadest enforceable boundary)
- Product/composition claim: defined API plus excipient system, with a defined composition “comprising” framework.
- Process claim (if present): stepwise preparation of the composition, with essential conditions.
- Use claim (if present): administration of the composition to treat/prevent the target condition.
Dependent claim layer (patentability moat)
Common dependent-claim narrowing patterns for CN113645966-style filings:
- Component substitution: specifying one excipient from a defined list (or restricting to a narrower subset).
- Ratio restrictions: tightening composition percentages.
- Particle/morphology properties: narrowing D50 or equivalent size metrics, or specifying polymorph/solid state.
- Manufacturing conditions: temperature, time, mixing speed, humidity, drying time, or sterilization parameters.
- Dosage form constraints: tablet/capsule/granule/suspension form, coating type, disintegration behavior, or dissolution test thresholds.
Where does CN113645966 sit in the China patent landscape?
A China “scope and claims” analysis must be anchored to landscape structure: who else owns similar formulation/process patents around the same API and indication, and whether CN113645966 is likely first-in-class (broad composition foundation) or a follow-on (parameter and process refinement).
Landscape mapping by claim type
For CN113645966, the landscape position typically splits into two competitive clusters:
-
Composition/excipient family patents
- Prior patents on the same API often exist around:
- bioavailability improvement
- stability (light, moisture, oxidation)
- controlled release
- taste-masking
- solubilization and wetting systems
- CN113645966’s differentiator is usually one of:
- a specific excipient combination
- critical ratio bands
- a solid state or particle property constraint
-
Process/solid-state/formulation patents
- If CN113645966 includes process claims, the main competitor sets usually include:
- melt/granulation methods
- coating processes
- drying/particle-size control methods
- polymorph or amorphous conversion methods
How to read CN113645966 against likely competitors
The practical patentability and freedom-to-operate question in China is:
- Does CN113645966 require a specific combination or specific parameter thresholds that others do not?
- Are competing filings using a different excipient class (or different ratios)?
- Are they producing a different solid state form (or different particle size distribution)?
- Are they using a different process pathway that avoids the essential steps in CN113645966’s process claim?
What are the scope-critical claim terms that drive infringement risk?
For a CN composition/process patent, infringement risk is driven by whether the accused product/process meets:
- API identity (same compound vs. salt/polymorph variants)
- Excipient identity (specific excipients vs. substitutes)
- Quantitative ratio (exact ranges)
- Structural/material constraints (particle size, polymorph, solid state)
- Processing conditions (time/temp/mixing method)
- Dosage form and administration form (tablet vs. capsule vs. suspension)
In business terms, the key question is not “does it treat the same disease” but “does it do so using the same technical limitations.”
What does this mean for freedom-to-operate (FTO) and design-around strategy?
If CN113645966’s independent claim is composition-based, a credible design-around usually targets one of these axes:
- Replace at least one required excipient with a non-equivalent or excluded excipient that CN113645966 does not define as permissible.
- Adjust ratios to exit the claimed bands.
- Switch solid-state form or particle property targets.
- Use a different manufacturing pathway that omits essential steps or conditions.
If CN113645966’s independent claim is process-based, design-around usually requires:
- Changing the order of steps
- Changing critical process parameters
- Using a different equipment pathway or method that avoids the claim’s “required” process conditions
Key patent landscape implications for investors and R&D teams
CN113645966 belongs to a class of China patents that typically provide:
- Short-to-medium competitive blocking (when tied to a formulation/process)
- Strong enforceability if dependent claims lock down critical parameters (ratio ranges, material properties, and processing steps)
- Moderate enforceability against generic “same API” products if the independent claim is narrow on excipients/ratios or solid-state metrics
Key Takeaways
- CN113645966 (CN113645966A) is a China invention patent with a composition/process-focused claim architecture that relies on specific technical limitations (API, excipients, ratios, and/or manufacturing or material properties).
- Its enforceable boundary is set by the independent claim; dependent claims refine those limits and often provide the moat via quantitative and process/material constraints.
- Landscape competition typically clusters by composition/excipient families and process/solid-state pathways; design-around must avoid at least one independent-claim required limitation.
FAQs
1) Does CN113645966 protect the API itself or the formulation?
It protects the formulation and/or preparation defined in the independent claims, with scope typically limited by excipient system, ratios, processing conditions, and/or material properties.
2) If a competitor uses the same API, are they automatically covered?
No. China formulation patents usually require matching all required technical limitations in the independent claim. The scope turns on excipient identity, ratio bands, and any material/process constraints.
3) What usually creates the strongest infringement risk for follow-on products?
Matching the independent claim’s combination of API + required excipients/ratios and any solid-state or process parameters specified as claim limitations.
4) What are the most common design-around levers in China formulation patents?
Excipient substitution, shifting component ratios out of claimed ranges, changing solid-state/particle properties, or altering the manufacturing process to avoid required steps/conditions.
5) How should R&D teams prioritize landscape work around CN113645966?
Map other CN patents and applications covering the same API and indication into two buckets: composition/excipient and process/solid-state. Then test candidate products against the independent-claim required limitations first.
References
[1] CN113645966A. China patent application publication CN113645966A.
